Carret Asset Management LLC Lowers Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Carret Asset Management LLC reduced its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 103,638 shares of the company’s stock after selling 1,007 shares during the period. Johnson & Johnson makes up approximately 2.5% of Carret Asset Management LLC’s holdings, making the stock its 6th largest holding. Carret Asset Management LLC’s holdings in Johnson & Johnson were worth $18,308,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of JNJ. Price T Rowe Associates Inc. MD grew its stake in shares of Johnson & Johnson by 18.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after purchasing an additional 3,912,430 shares during the period. FMR LLC grew its position in Johnson & Johnson by 20.8% during the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after acquiring an additional 3,229,032 shares during the last quarter. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after acquiring an additional 2,815,655 shares during the last quarter. GQG Partners LLC grew its position in Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in Johnson & Johnson by 52.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after acquiring an additional 2,093,392 shares during the last quarter. 67.94% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Atlantic Securities increased their price target on Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 25th. StockNews.com assumed coverage on Johnson & Johnson in a research report on Thursday. They set a “strong-buy” rating on the stock. Guggenheim initiated coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target on the stock. Piper Sandler reduced their price objective on Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Finally, Citigroup upped their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, December 12th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.73.

Johnson & Johnson Stock Performance

JNJ stock opened at $152.38 on Friday. The business’s fifty day moving average is $161.97 and its 200-day moving average is $167.91. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. The company has a market cap of $396.84 billion, a P/E ratio of 22.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.54. Johnson & Johnson has a twelve month low of $150.71 and a twelve month high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. The company had revenue of $23.71 billion for the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The firm’s quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.13 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.5 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.97%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s payout ratio is presently 67.06%.

Insider Buying and Selling

In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.